Relevant considerations for when to expect revenue can be taken from the prospectus. From page 147, the 60million in class B performance shares vest only if cumulative revenue exceeds $US 30m in any 12 month period within 2 years of listing.
Furthermore, from page 106, if the company has not commenced sales within 12 months of listing then Dr Gevas salary is reduced to zero until sales commence.
Therefore the management have a strong incentive to start sales by May 2018 (at the latest) and to get annual sales up to $US30m before May 2019 .
GMV Price at posting:
33.5¢ Sentiment: Hold Disclosure: Held
